Search

Your search keyword '"Franke, Molly F."' showing total 497 results
Start Over Author "Franke, Molly F."
497 results on '"Franke, Molly F."'

1. Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA

Author

Matias, Wilfredo R., Fulcher, Isabel R., Sauer, Sara M., Nolan, Cody P., Guillaume, Yodeline, Zhu, Jack, Molano, Francisco J., Uceta, Elizabeth, Collins, Shannon, Slater, Damien M., Sánchez, Vanessa M., Moheed, Serina, Harris, Jason B., Charles, Richelle C., Paxton, Ryan M., Gonsalves, Sean F., Franke, Molly F., and Ivers, Louise C.

Published
2024
Full Text
View/download PDF

2. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis

Author

James, Lyndon P., Klaassen, Fayette, Sweeney, Sedona, Furin, Jennifer, Franke, Molly F., Yaesoubi, Reza, Chesov, Dumitru, Ciobanu, Nelly, Codreanu, Alexandru, Crudu, Valeriu, Cohen, Ted, and Menzies, Nicolas A.

Subjects
Moldova -- Health aspects, Antitubercular agents -- Dosage and administration -- Physiological aspects -- Economic aspects, Pharmacology, Experimental, Drug therapy, Combination -- Physiological aspects -- Economic aspects -- Models, Tuberculosis -- Drug therapy -- Models -- Physiological aspects, Biological sciences
Abstract

Background Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether fluoroquinolone resistance (FQ-R) was detected on drug susceptibility testing (DST). Methods and findings The primary objective was to determine whether 6 months of BPaLM is a cost-effective treatment strategy for RR-TB. We used genomic and demographic data to parameterize a mathematical model estimating long-term health outcomes measured in quality-adjusted life years (QALYs) and lifetime costs in 2022 USD ($) for each treatment strategy for patients 15 years and older diagnosed with pulmonary RR-TB in Moldova, a country with a high burden of TB drug resistance. For each individual, we simulated the natural history of TB and associated treatment outcomes, as well as the process of acquiring resistance to each of 12 anti-TB drugs. Compared to the standard of care, 6 months of BPaLM was cost-effective. This strategy was estimated to reduce lifetime costs by $3,366 (95% UI: [1,465, 5,742] p < 0.001) per individual, with a nonsignificant change in QALYs (-0.06; 95% UI: [-0.49, 0.03] p = 0.790). For those stopping moxifloxacin under the BPaLM regimen, continuing with BPaL plus clofazimine (BPaLC) provided more QALYs at lower cost than continuing with BPaL alone. Strategies based on 6 months of BPaLM had at least a 93% chance of being cost-effective, so long as BPaLC was continued in the event of stopping moxifloxacin. BPaLM for 6 months also reduced the average time spent with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it increased the average time spent with TB resistant to delamanid and pretomanid. Sensitivity analyses showed 6 months of BPaLM to be cost-effective across a broad range of values for the relative effectiveness of BPaLM, and the proportion of the cohort with FQ-R. Compared to the standard of care, 6 months of BPaLM would be expected to save Moldova's national TB program budget $7.1 million (95% UI: [1.3 million, 15.4 million] p = 0.002) over the 5-year period from implementation. Our analysis did not account for all possible interactions between specific drugs with regard to treatment outcomes, resistance acquisition, or the consequences of specific types of severe adverse events, nor did we model how the intervention may affect TB transmission dynamics. Conclusions Compared to standard of care, longer regimens, the implementation of the 6-month BPaLM regimen could improve the cost-effectiveness of care for individuals diagnosed with RR-TB, particularly in settings with a high burden of drug-resistant TB. Further research may be warranted to explore the impact and cost-effectiveness of shorter RR-TB regimens across settings with varied drug-resistant TB burdens and national income levels., Author(s): Lyndon P. James 1,2,*, Fayette Klaassen 3, Sedona Sweeney 4, Jennifer Furin 5, Molly F. Franke 5, Reza Yaesoubi 6, Dumitru Chesov 7,8, Nelly Ciobanu 9, Alexandru Codreanu 9, [...]

Published
2024
Full Text
View/download PDF

5. Seroprevalence of Vibrio cholerae in Adults, Haiti, 2017

Author

Matias, Wilfredo R., Guillaume, Yodeline, Augustin, Gertrude Cene, Vissieres, Kenia, Ternier, Ralph, Charles, Richelle C., Harris, Jason B., Franke, Molly F., and Ivers, Louise C.

Subjects
Cholera toxin -- Health aspects, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Communicable diseases -- Health aspects, Viral antibodies -- Health aspects, Public health -- Health aspects, Adults -- Health aspects, Antibodies -- Health aspects, Cholera -- Health aspects, Health
Abstract

In 2010, cholera, caused by the bacterium Vibrio cholerae, was introduced into Haiti, resulting in >800,000 cases and >10,000 deaths (1,2). Case incidence peaked in 2012, then decreased, and the [...]

Published
2023
Full Text
View/download PDF

10. Evaluation of the Access Bio CareStart rapid SARS-CoV-2 antigen test in asymptomatic individuals tested at a community mass-testing program in Western Massachusetts

Author

Suliman, Sara, Matias, Wilfredo R., Fulcher, Isabel R., Molano, Francisco J., Collins, Shannon, Uceta, Elizabeth, Zhu, Jack, Paxton, Ryan M., Gonsalves, Sean F., Harden, Maegan V., Fisher, Marissa, Meldrim, Jim, Gabriel, Stacey, Franke, Molly F., Hung, Deborah T., Smole, Sandra C., Madoff, Lawrence C., and Ivers, Louise C.

Published
2022
Full Text
View/download PDF

11. Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in Lesotho

Author

Oyewusi, Lawrence, primary, Zeng, Chengbo, additional, Seung, KJ, additional, Mpinda, Stephanie, additional, Kunda, Mikanda, additional, Mitnick, Carole D, additional, Kanu, Makelele, additional, Tamirat, Meseret, additional, Makaka, Joalane, additional, Mofolo, Mabatloung, additional, Maime, Refiloe, additional, Maama, Llang, additional, Senyo, Ninza, additional, Oguntoyinbo, Bamidele, additional, Mayombo, Lwayi, additional, and Franke, Molly F, additional

Published
2024
Full Text
View/download PDF

14. Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosis

Author

Zeng, Chengbo, primary, Hernan, Miguel A., additional, Trevisi, Letizia, additional, Sauer, Sara, additional, Mitnick, Carole D., additional, Hewison, Catherine, additional, Bastard, Mathieu, additional, Khan, Palwasha, additional, Seung, Kwonjune J., additional, Rich, Michael L., additional, Law, Stephaine, additional, Kikvidze, Marina, additional, Kirakosyan, Ohanna, additional, Miankou, Alexey, additional, Thit, Phone, additional, Mamsa, Shahid, additional, Janmohamed, Aleeza, additional, Melikyan, Nara, additional, Ahmed, Saman, additional, Vargas, Dante, additional, Binegdie, Amsalu Bekele, additional, Temirova, Kulbaram, additional, Oyewusi, Lawrence, additional, Philippe, Kerline, additional, Vilbrun, Stalz C., additional, Khan, Uzma, additional, Huerga, Helena, additional, and Franke, Molly F., additional

Published
2024
Full Text
View/download PDF

18. Retention and Viral Suppression Among Adolescents Newly Initiating Antiretroviral Therapy in Adult HIV Care in Lima, Peru: A Retrospective Cohort Study

Author

Niwa, Miyu, primary, Matos, Eduardo, additional, Rodriguez, Carly, additional, Wong, Milagros, additional, Errea, Renato A., additional, Ramos, Alicia, additional, Senador, Liz, additional, Contreras, Carmen, additional, Galea, Jerome T., additional, Lindeborg, Andrew, additional, Benites, Carlos, additional, Shin, Sonya S., additional, Lecca, Leonid, additional, and Franke, Molly F., additional

Published
2023
Full Text
View/download PDF

19. Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Author

Lotia Farrukh, Ismat, primary, Lachenal, Nathalie, additional, Adenov, Malik M, additional, Ahmed, Saman, additional, Algozhin, Yerkebulan, additional, Coutisson, Sylvine, additional, Garavito, Epifanio Sánchez, additional, Hewison, Catherine, additional, Holtzman, David, additional, Huerga, Helena, additional, Janmohamed, Aleeza, additional, Khan, Palwasha Y, additional, Jacques, Gamarly Leblanc, additional, Lomtadze, Nino, additional, Melikyan, Nara, additional, Mitnick, Carole D, additional, Mussabekova, Gulnaz, additional, Osso, Elna, additional, Perea, Sara, additional, Putri, Fauziah Asnely, additional, Rashidov, Mahmud, additional, Rich, Michael L, additional, Sakhabutdinova, Yekaterina, additional, Seung, Kwonjune J, additional, Stambekova, Assel, additional, Vásquez, Dante Vargas, additional, Franke, Molly F, additional, and Khan, Uzma, additional

Published
2023
Full Text
View/download PDF

24. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis: a mathematical modeling analysis

Author

James, Lyndon P, primary, Klaassen, Fayette, additional, Sweeney, Sedona, additional, Furin, Jennifer, additional, Franke, Molly F, additional, Yaesoubi, Reza, additional, Chesov, Dumitru, additional, Ciobanu, Nelly, additional, Codreanu, Alexandru, additional, Crudu, Valeriu, additional, Cohen, Ted, additional, and Menzies, Nicolas A, additional

Published
2023
Full Text
View/download PDF

26. Respiratory, Cardiac, and Neuropsychiatric Manifestations of Postacute Sequelae of Coronavirus Disease 2019 in Lima, Peru

Author

Rahman, Rifat S, primary, Tovar, Marco A, additional, Peinado, Jesús, additional, Palomino, J Santiago, additional, Ramirez, Claudio, additional, Llanos-Zavalaga, Fernando, additional, Peralta, Ernesto, additional, Valderrama, Gissela, additional, Ramos Cordova, Lourdes B, additional, Sanchez Cortez, Lucero I, additional, Rodriguez, German, additional, LaHood, Allison N, additional, Franke, Molly F, additional, Mitnick, Carole D, additional, Lecca, Leonid, additional, and Velásquez, Gustavo E, additional

Published
2023
Full Text
View/download PDF

29. Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis

Author

Gunasekera, Kenneth S, primary, Marcy, Olivier, additional, Muñoz, Johanna, additional, Lopez-Varela, Elisa, additional, Sekadde, Moorine P, additional, Franke, Molly F, additional, Bonnet, Maryline, additional, Ahmed, Shakil, additional, Amanullah, Farhana, additional, Anwar, Aliya, additional, Augusto, Orvalho, additional, Aurilio, Rafaela Baroni, additional, Banu, Sayera, additional, Batool, Iraj, additional, Brands, Annemieke, additional, Cain, Kevin P, additional, Carratalá-Castro, Lucía, additional, Caws, Maxine, additional, Click, Eleanor S, additional, Cranmer, Lisa M, additional, García-Basteiro, Alberto L, additional, Hesseling, Anneke C, additional, Huynh, Julie, additional, Kabir, Senjuti, additional, Lecca, Leonid, additional, Mandalakas, Anna, additional, Mavhunga, Farai, additional, Myint, Aye Aye, additional, Myo, Kyaw, additional, Nampijja, Dorah, additional, Nicol, Mark P, additional, Orikiriza, Patrick, additional, Palmer, Megan, additional, Sant'Anna, Clemax Couto, additional, Siddiqui, Sara Ahmed, additional, Smith, Jonathan P, additional, Song, Rinn, additional, Thuong Thuong, Nguyen Thuy, additional, Ung, Vibol, additional, van der Zalm, Marieke M, additional, Verkuijl, Sabine, additional, Viney, Kerri, additional, Walters, Elisabetta G, additional, Warren, Joshua L, additional, Zar, Heather J, additional, Marais, Ben J, additional, Graham, Stephen M, additional, Debray, Thomas P A, additional, Cohen, Ted, additional, and Seddon, James A, additional

Published
2023
Full Text
View/download PDF

35. Effectiveness of Bedaquiline Use Beyond Six Months in Patients with Multidrug-Resistant Tuberculosis

Author

Trevisi, Letizia, primary, Hernán, Miguel A., additional, Mitnick, Carole D, additional, Khan, Uzma, additional, Seung, Kwonjune J, additional, Rich, Michael L., additional, Bastard, Mathieu, additional, Huerga, Helena, additional, Melikyan, Nara, additional, Atwood, Sidney, additional, Avaliani, Zaza, additional, Llanos, Felix, additional, Manzur-ul-Alam, Mohammed, additional, Zarli, Khin, additional, Binedgie, Amsalu Bekele, additional, Adnan, Sana, additional, Melikyan, Arusyak, additional, Gelin, Alain, additional, Isani, Afshan K, additional, Vetushko, Dmitry, additional, Daugarina, Zhenisgul, additional, Nkundanyirazo, Patrick, additional, Putri, Fauziah Asnely, additional, Vilbrun, Charles, additional, Khan, Munira, additional, Hewison, Catherine, additional, Khan, Palwasha Y, additional, and Franke, Molly F, additional

Published
2023
Full Text
View/download PDF

43. Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA

Author

Matias, Wilfredo R., primary, Fulcher, Isabel R., additional, Sauer, Sara M., additional, Nolan, Cody P., additional, Guillaume, Yodeline, additional, Zhu, Jack, additional, Molano, Francisco J., additional, Uceta, Elizabeth, additional, Collins, Shannon, additional, Slater, Damien M., additional, Sánchez, Vanessa M., additional, Moheed, Serina, additional, Harris, Jason B., additional, Charles, Richelle C., additional, Paxton, Ryan M., additional, Gonsalves, Sean F., additional, Franke, Molly F., additional, and Ivers, Louise C., additional

Published
2023
Full Text
View/download PDF

47. Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion

Author

Rodriguez, Carly A., primary, Lodi, Sara, additional, Horsburgh, C. Robert, additional, Bastard, Mathieu, additional, Hewison, Cathy, additional, Huerga, Helena, additional, Khan, Munira, additional, Khan, Palwasha Y., additional, Khan, Uzma, additional, Oyewusi, Lawrence, additional, Padayachee, Shrivani, additional, Mitnick, Carole D., additional, and Franke, Molly F., additional

Published
2022
Full Text
View/download PDF

48. Additional file 1 of Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru

Author

Law, Stephanie, Tovar, Marco A., Franke, Molly F., Calderon, Roger, Palomino, Santiago, Valderrama, Gissella, Llanos, Fernando, Velásquez, Gustavo E., Mitnick, Carole D., and Lecca, Leonid

Abstract

Additional file 1. Table S1. Reported symptoms of all participants with sample collected (and tested) for serologic antibody test on same day as sample that resulted in RT-PCR positive for SARS-CoV-2 (n=492); no symptom duration outliers excluded. Table S2. Reported symptoms of all participants with sample collected (and tested) for serologic antibody test on same day as sample that resulted in RT-PCR positive for SARS-CoV-2 (n=492); mild and extreme symptom duration outliers excluded. Table S3. Sensitivity of the rapid antibody test# by symptom duration and outlier exclusion criteria. Fig. S1. Plots of antibody test sensitivity against the number of weeks since onset of symptoms among those who reported at least one symptom before testing, using the RT-PCR test as the reference, stratified by the types of outliers excluded in the analysis: extreme outliers, which were defined as persons whose time since symptom onset was longer than the third quartile plus 3 times the interquartile range (IQR, defined as the difference between the first and third quartile of the reported times since onset for a given symptom); mild outliers were those beyond the third quartile plus 1.5 times the IQR); or no outliers excluded. The circles show the crude estimated sensitivity and the error bars show the Wilson’s score 95% confidence intervals. The plotted lines are the fitted segmented linear regressions for the rapid antibody tests. Table S4. Segmented regression analyses of antibody test sensitivity by weeks since symptom onset, by symptom duration outlier exclusion criteria. Table S5. Overall antibody test sensitivity* per week since symptom onset for common symptoms. Table S6.Segmented regression analyses of antibody test sensitivity versus weeks since symptom onset, by symptom.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results